The study was undertaken to evaluate cardiorespiratory fitness, skeletal muscle function, and body composition of patients with newly diagnosed and untreated, postsurgical primary malignant glioma.

METHODS:

By using a cross-sectional design, patients with clinically stable (10 ± 7 days postsurgery) high-grade glioma (HGG; n = 25) or low-grade glioma (LGG; n = 10) were studied. Participants performed a cardiopulmonary exercise test (CPET) with expired gas analysis to assess cardiorespiratory fitness (peak oxygen consumption, VO_2peak). Other physiological outcomes included skeletal muscle cross-sectional area (CSA; magnetic resonance imaging), isokinetic muscle strength (isokinetic dynamometer), and body composition (air displacement plethysmography). Quality of life was assessed with the Functional Assessment of Cancer Therapy-Brain scale.

RESULTS:

CPET was a feasible and safe procedure to assess VO_2peak, with no serious adverse events. VO_2peak indexed to total body weight and lean body mass (LBM) for both groups was 13.0 mL · weight · min⁻¹ and 19 mL · LBM · min⁻¹, the equivalent to 59% and 38% below age- and sex-predicted normative values, respectively. Skeletal muscle strength and mid-thigh CSA were lower in HGG relative to LGG patients (83 vs 125 Nm, P = .025; 94 vs 119 cm², P = .171, respectively). Skeletal muscle isokinetic strength, CSA, and body composition outcomes predicted VO_2peak (r = −0.59 to 0.68, P < .05).

CONCLUSIONS:

Postsurgical glioma patients have markedly reduced cardiorespiratory fitness, isokinetic strength, and CSA. Prospective studies are now required to determine whether such abnormalities influence treatment toxicity and clinical outcome as well as to test the effect of appropriately selected interventions to prevent and/or mitigate dysfunction. Cancer 2010. © 2009 American Cancer Society.

Malignant gliomas remain 1 of the greatest challenges in oncology. Despite aggressive therapy, overall survival of patients with newly diagnosed glioblastoma multiforme, the most common malignant glioma, is 42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years.1 The development of neuropsychological symptoms and cognitive dysfunction has been researched extensively in malignant glioma, with neurocognitive functioning now seen as a legitimate and viable clinical endpoint in glioma management and clinical trials.2 The physiological or functional sequelae have, in contrast, received scant attention.

The effect of standard regional and systemic therapy on functional parameters (eg, exercise capacity, body composition) has been investigated in several cancer populations.3-6 However, the use of high-dose corticosteroids in malignant glioma is of particular concern. Chronic corticosteroid therapy use is associated with skeletal muscle atrophy and weakness as well as ultrastructural abnormalities in myofibrillar mass, mitochondrial volume, and capillary number.7-9 Together with secondary effects on physical activity levels (ie, deconditioning), steroid therapy is expected to have profound effects on patients' exercise tolerance, ability to perform activities of daily living, and even clinical outcome.10

With an emerging new treatment paradigm in malignant glioma, characterized by increased use of antiangiogenic agents in combination with standard cytotoxic therapy,11 clinical tools that quantitatively evaluate functional outcome are set to become an increasingly important aspect of multidisciplinary care. These tools can be used to improve prognostication, to determine whether patients are able to tolerate a particular therapeutic regimen, and to identify those at high risk of functional complications so appropriate preventive and/or treatment interventions can be initiated.12

Formalized objective measures of cardiorespiratory fitness (peak oxygen consumption, VO_2peak) are widely used in many areas of clinical practice and are powerful predictors of mortality.12 Measures of skeletal muscle function including muscle strength, cross-sectional area (CSA), and whole-body composition (lean body mass [LBM] vs body mass) are central determinants of reduced exercise tolerance in chronic heart failure (CHF)13 and heart transplant patients.14 Heart transplant patients, similar to malignant glioma, suffer disease- and/or corticosteroid-induced skeletal myopathy. Muscle wasting is also an independent predictor of mortality in CHF.15 As an initial step, we conducted a pilot study to evaluate cardiorespiratory fitness, skeletal muscle function, and body composition among 35 clinically stable, newly diagnosed and untreated, postsurgical high-grade or low-grade glioma patients. A secondary aim was to determine the relationship between quantitative functional endpoints, quality of life (QOL), and fatigue.

MATERIALS AND METHODS

Participants and Setting

The study was conducted at the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina. Patients with histologically confirmed, clinically stable, postsurgical, and previously untreated glioma (World Health Organization grade 1-4) were potentially eligible for this study. Additional major inclusion criteria included: 1) Karnofsky performance status (KPS) of ≥70%, 2) estimated life expectancy of ≥6 months, 3) no contraindications to a cardiopulmonary exercise test (CPET),12 and 4) primary oncologist approval. The Duke University Medical Center Institutional Review Board approved the study, and written informed consent was obtained from all participants before initiation of any study procedures.

Study Procedures

By using a cross-sectional design, all potential participants were identified and screened for eligibility via medical chart review of patients scheduled for their postsurgical treatment consultation at the Preston Robert Tisch Brain Tumor Center. After obtaining written informed consent, all participants were scheduled for study assessments. All study-related assessments were performed at Duke University Medical Center within a 2-day period by study staff blinded to group assignment (ie, high- vs low-grade diagnosis).

Outcome Assessments

Incremental cardiorespiratory exercise testing

To determine VO_2peak, an incremental, physician-supervised CPET with 12-lead electrocardiographic monitoring (Mac 5000, GE Healthcare, Little Chalfont, UK) was performed according to guidelines published by Jones et al.12 All tests were performed on an electronically braked cycle ergometer (Ergoline, Ergoselect 100, Bitz, Germany) with died gas analysis (ParvoMedics TrueOne 2400, Sandy, Utah). Preceding exercise, 3 minutes of resting metabolic data were collected before participants began cycling at 10 to 20 W. Workloads were then increased 5 to 20 W/min until volitional exhaustion, symptom limitation, or a respiratory exchange ratio (RER) of >1.0 was achieved. Tests were terminated when a RER >1.0 was achieved because all subjects had recently undergone craniotomy; the safety and feasibility of maximal CPETs (RER >1.10) in this setting is unknown, thus we felt it was prudent to terminate tests once adequate test criteria had been achieved for clinical populations.12 Initial workload and workload increments were determined by patients' medical history and metabolic responses to exercise during the first minute. During exercise, blood pressure was measured noninvasively by manual auscultatory sphygmomanometry every 2 minutes.16 At the end of each workload, rating of perceived exertion was evaluated using the Borg scale.17 The metabolic measurement system was calibrated before and the calibration was checked after each test. Patients continued with usual medications and were asked to abstain from caffeinated beverages on the day of testing. All cardiopulmonary function data were recorded as the highest 30 seconds value elicited during the CPET. Mean percentage of age- and sex-predicted peak heart rate and VO_2peak were calculated from the equations provided by Jones et al18 and Fitzgerald et al19 (women) and Wilson and Tanaka20 (men), respectively.

Skeletal muscle function

Muscle CSA of the dominant thigh was assessed using magnetic resonance imaging (MRI) with a 3.0-T scanner (Phillips ACS II, Shelton, Conn). Imaging was performed using sequence gradient echo recall scans at the midfemur level. Seven serial slices were obtained with 1 at the juncture of the middle third of the femur (this point will be landmarked to ensure within-patient reproducibility) as previously described.21 The CSA of the quadriceps, hamstrings, and total midthigh muscle was assessed using semiautomatic (manual) generation of the region of interest using console software by 1 investigator (M.I.T.) blinded to group assignment.

Muscle strength of the right quadriceps was measured using a Biodex isokinetic dynamometer (Biodex Medical Systems, Shirley, NY). The isokinetic testing protocols consisted of 3 sequential voluntary maximal contractions at an angular velocity of 90^°/s. Maximal isokinetic strength was defined as the highest peak torque achieved during the 3 contractions. Mean percentage of age- and sex-predicted muscle strength was obtained from prior reports.22

Body composition

Percent body fat, fat mass (FM), and LBM were evaluated by air-displacement plethysmography (eg, BOD POD, Life Measurement Incorporated, Concord, Calif). In brief, each patient wore spandex and cap provided by the laboratory while body mass was measured to the nearest 100 g followed by the calculation of thoracic gas volume. Body density was calculated as body mass divided by body volume. Percent body fat was estimated from body density based on a 2-compartment model. The system was calibrated before each test, and 1 investigator (S.K.M.) conducted all body composition assessments. Mean percentage of age- and sex-predicted LBM and FM was obtained from prior reports.23, 24 The test-retest reliability of BOD POD for body composition assessment is 0.99425; it is widely regarded as a valid and reliable method to assess body composition in middle-aged and elderly subjects.26, 27

QOL

QOL was assessed using the Functional Assessment of Cancer Therapy (FACT) Brain scale.28 The FACT-Brain contains subscales for physical (7 items), functional (7 items), emotional (6 items), and social/family (7 items) well-being. In addition, the FACT-Brain contains a 19-item brain cancer subscale, which assesses symptoms commonly reported by brain cancer patients.28 Fatigue was assessed by the 13-item Fatigue scale of the FACT measurement system developed specifically for cancer patients.29

Clinical Parameters and Performance Status

Medical characteristics were abstracted from medical records. Performance status (PS) was assessed using the KPS scale and was assessed at the time of study enrollment by the attending oncologist. KPS scores range from 0 (dead) to 100 (normal; no evidence of disease and no physical complaints). Self-reported exercise over the past month was assessed by the Godin Leisure Time Exercise Questionnaire.30

Statistical Analysis

The initial analysis provided descriptive information on the demographic and clinical treatment characteristics of participants. To examine differences between patients with high-grade glioma (HGG) and low-grade glioma (LGG) (overall as well as by sex) in study endpoints, we used a series of independent samples t tests. Linear regression analysis was used to determine the univariate association between study endpoints. Data are presented as mean ± standard deviation. All statistical tests were 2-sided, and significance was prespecified at P < .05. No adjustment was made for multiple tests.

RESULTS

Participant recruitment took place between October 2006 and July 2008. In brief, 131 patients were screened for study eligibility during the study period. Of these, 69 (53%) met inclusion criteria, and 35 (51%) agreed to participate. Major reasons for ineligibility were KPS <70% (n = 11), mental distress (n = 5), and postoperative complications (n = 5). Major reasons for study refusal were not interested (n = 21) and feeling overwhelmed (n = 5). The participants' demographic and clinical characteristics are shown in Table 1. Muscle CSA was only obtained in 20 patients (low grade, n = 7; high grade, n = 13). Reasons for not obtaining this assessment were patient MRI contraindications and equipment maintenance.

Table 1. Characteristics of the Participantsa

Variable	Overall (N=35)	High-Grade Patients (n=25)	Low-Grade Patients (n=10)
Age, y
Mean	47 ± 13	50 ± 13	40 ± 8
Range	22-77	22-77	30-54
Sex, No. (%)
Men	21 (60)	15 (60)	6 (60)
Women	14 (40)	10 (40)	4 (40)
Histology, No. (%)
Grade 4	19 (54)	19 (76)	—
Grade 3	6 (17)	6 (24)	—
Grade 2	8 (80)	—	8 (80)
Grade 1	2 (20)	—	2 (20)
Karnofsky performance status, No. (%)
100%	10 (28)	3 (12)	7 (70)
90%	10 (28)	9 (36)	1 (10)
80%	14 (41)	12 (48)	2 (20)
70%	1 (3)	1 (4)	0 (0)
Hemoglobin, g/dL
Mean	13 ± 2.0	13 ± 2.0	13 ± 2.0
Range	9-16	9-16	9-15
Concomitant comorbidities, No. (%)
Lower extremity weakness	4 (11)	4 (16)	—
Hypertension	4 (11)	2 (16)	2 (20)
Coronary artery disease	3 (9)	3 (12)	—
Previous malignancy	2 (6)	2 (8)	—
Type II diabetes mellitus	1 (3)	1 (4)	—
Ataxia	1 (3)	1 (4)	—
Extent of resection, No. (%)
Biopsy	2 (6)	1 (4)	1 (10)
Debulking	33 (94)	24 (96)	9 (90)
Complete resection	27 (84)	19 (83)	8 (89)
Partial resection	5 (16)	4 (17)	1 (11)
Time from surgery to study entry, d
Mean	10 ± 7	9 ± 6	12 ± 10
Range	4-30	4-25	4-30
Presurgical corticosteroid therapy, No. (%)	34 (97)	24 (96)	10 (100)
Mean dose, mg (range)	82 (30-120)	83 (30-120)	82 (40-110)
Postsurgical corticosteroid therapy, No. (%)	35 (100)	25 (100)	10 (100)
Mean dose, mg (range)	7 (1-20)	7 (1-10)	7 (1-20)
Exercise behavior
Total min/wk	70 ± 109	79 ± 121	48 ± 73
No exercise behavior [ie, 0 min/wk] (%)	17 (49)	12 (48)	5 (50)

a Data are presented as the mean ± standard deviation for continuous variables and as number (%) for categorical variables.

Cardiopulmonary Exercise Test Abnormalities and Adverse Events

Across the entire study sample (n = 35), 33 (94%) CPETs were considered to be of adequate effort given that a respiratory exchange ratio of >1.0 was achieved (1 patient was unable to perform the CPET because of an equipment malfunction). The 1 patient who did not achieve this criterion stopped prematurely because of exercise-induced desaturation (oxygen saturation as measured using pulse oximetry <85%), which normalized after exercise termination.

Physiological Data

In HGG patients, VO_2peak averaged 13 ± 4 mL · weight · min⁻¹ (range, 8-26 mL · weight · min⁻¹), the equivalent to 59% below age- and sex-predicted normative values. Peak heart rate was 120 ± 22 beats · min⁻¹ or 71% of age-predicted maximum (VO_2peak typically is achieved at ≥85% of peak heart rate in healthy adults), and peak workload averaged 66 ± 43 W. Mean total midthigh CSA and muscle strength were 94 ± 32 cm² and 83 ± 42 Nm, respectively. Percentage body fat, FM, and LBM were 30 ± 11%, 23 ± 11 kg, and 53 ± 14 kg, respectively. In patients with LGG, peak VO₂ averaged 13 ± 4 mL · weight · min⁻¹ (range, 8-19 mL · weight · min⁻¹), the equivalent to 62% below age- and sex-predicted normative values. Mean total midthigh CSA and muscle strength were 119 ± 44 cm² and 124 ± 54 Nm, respectively. Percent body fat, FM, and LBM were 34 ± 8%, 29 ± 12 kg, and 56 ± 14 kg, respectively. Only muscle strength was significantly different between groups (P = .025) (Table 2). We also examined differences in physiological data between male and female participants according to primary glioma diagnosis (ie, HGG vs LGG). Results indicated that peak workload, LBM, and muscle strength (P's <.05) were significantly higher in women with LGG. There were no significant differences between men according to primary glioma diagnosis (analysis of variance).

Table 2. Physiologic Dataa

Variable	Overall (N=35)	High-Grade Patients (n=25)	Low-Grade Patients (n=10)	P
Resting cardiovascular function
Heart rate, beats/min	74 ± 12	74 ± 14	73 ± 8	.800
Systolic blood pressure, mm Hg	124 ± 13	125 ± 14	123 ± 11	.753
Diastolic blood pressure, mm Hg	78 ± 8	77 ± 14	80 ± 5	.239
Peak cardiovascular function
Heart rate, beats/min	120 ± 22	120 ± 22	119 ± 23	.903
Percent predicted, %	69 ± 12	71 ± 12	66 ± 12	.306
Systolic blood pressure, mm Hg	142 ± 18	140 ± 19	148 ± 15	.203
Diastolic blood pressure, mm Hg	84 ± 9	84 ± 10	85 ± 7	.812
VO_2peak, mL·weight⁻¹·min⁻¹	13 ± 4	13 ± 4	13 ± 4	.921
Percent predicted, %	41 ± 10	42 ± 9	38 ± 9	.279
VO_2peak, mL·lean⁻¹·min⁻¹	19 ± 5	19 ± 5	20 ± 5	.578
Percent predicted, %	62 ± 16	62 ± 15	57 ± 17	.460
VO_2peak, mL⁻¹·min⁻¹	1.04 ± 0.5	1.01 ± 0.5	1.11 ± 0.4	.565
Workload, W	68 ± 40	66 ± 43	73 ± 30	.672
O₂ pulse, mL O₂/beat	11 ± 3	11 ± 3	11 ± 2	.969
METS	3.8 ± 1.1	3.7 ± 1.2	3.8 ± 1.1	.889
Ventilation, L/min	32 ± 10	31 ± 11	33 ± 10	.690
Tidal volume, L	1.6 ± 0.6	1.6 ± 0.6	1.7 ± 0.5	.563
Respiratory rate	20 ± 5	21 ± 6	19 ± 4	.531
Respiratory exchange ratio	1.02 ± 0.05	1.02 ± 0.05	1.03 ± 0.03	.790
Rating of perceived exertion	13 ± 3	13 ± 6	14 ± 3	.422
Body composition
Weight, kg	79 ± 18	76 ± 17	85 ± 22	.182
Body mass index, kg/m²	26 ± 5	25 ± 4	28 ± 6	.085
Body fat, %	31 ± 10	30 ± 11	34 ± 8	.417
Fat mass, kg	25 ± 11	23 ± 11	29 ± 12	.152
% predicted	165 ± 76	150 ± 73	190 ± 70	.174
Lean body mass, kg	53 ± 14	53 ± 14	56 ± 14	.534
% predicted	96 ± 15	93 ± 13	101 ± 19	.189
Skeletal muscle function
Quadriceps CSA, cm2	54 ± 19	50 ± 17	67 ± 22	.157
Hamstrings CSA, cm²	48 ± 18	44 ± 16	56 ± 22	.204
Total thigh CSA, cm²	102 ± 37	94 ± 32	119 ± 44	.171
Muscle strength (torque), nM	94 ± 48	83 ± 42	124 ± 54	.025
% predicted	57 ± 28	50 ± 23	77 ± 30	.012

VO_2peak indicates peak oxygen consumption (mL · kg⁻¹ · min⁻¹); METS, metabolic equivalents; CSA, cross-sectional area.
a Data are presented as mean ± standard deviation for continuous variables and No. (%) for categorical variables.

QOL Data

In the HGG group, overall QOL (FACT-Brain) was 122 ± 21 (maximum score, 184; higher scores indicate better QOL), whereas fatigue was 30 ± 12 (maximum score, 52; higher scores indicate worse fatigue). In LGG patients, average overall QOL and fatigue were 132 ± 29 and 30 ± 12, respectively. There were no differences between patient groups on any QOL endpoint (Table 3).

Table 3. Quality of Life Dataa

FACT Quality of Life Variable	Overall (N=35)	High-Grade Patients (n=25)	Low-Grade Patients (n=10)	P
Brain, 0-184	125 ± 24	122 ± 21	132 ± 29	.325
General, 0-108	78 ± 15	79 ± 14	78 ± 19	.931
Physical well-being, 0-28	20 ± 6	20 ± 6	19 ± 8	.698
Functional well-being, 0-28	15 ± 6	16 ± 6	14 ± 7	.666
Social well-being, 0-28	24 ± 5	24 ± 3	24 ± 3	.350
Emotional well-being, 0-24	19 ± 4	19 ± 3	19 ± 3	.656
Brain cancer-specific subscale, 0-76	46 ± 12	44 ± 12	52 ± 12	.085
Fatigue, 0-52	22 ± 12	22 ± 12	21 ± 12	.873

FACT indicates Functional Assessment of Cancer Therapy.
a Data are presented as the mean ± standard deviation.

Univariate Prediction Analyses

Among HGG patients, univariate analysis revealed that several endpoints were significantly correlated with VO_2peak and total muscle CSA (r = −0.59 to 0.68, P < .05; r = −0.80 to 0.73, P < .05, respectively). Among LGG patients, only KPS was significantly correlated with VO_2peak (r = 0.72, P = .017), whereas FM, LBM, and muscle strength were correlated with total muscle CSA (r = 0.83-0.93, P < .05) (Table 4).

Table 4. Univariate Predictors of VO_2peak and Muscle CSA

Variable	High-Grade Patients (n=25)				Low-Grade Patients (n=10)
	VO_2peak		Muscle CSA		VO_2peak		Muscle CSA
	R	P	r	P	r	P	r	P
Medical/demographic
Age	−0.47	.022	−0.80	.001	−0.43	.211	−0.61	.143
Sexa	−0.50	.012	−0.50	.012	−0.01	.968	−0.50	.252
KPS	0.40	.050	0.22	.47	0.73	.017	0.28	.542
Postsurgery corticosteroid dose	0.35	.099	0.62	.024	0.02	.959	0.34	.453
Exercise behaviorb	0.01	.965	0.05	.855	0.08	.830	0.69	.083
Cardiovascular function
VO_2peak	—	—	0.40	.100	—	—	0.22	.629
Body composition
Fat percentage	−0.59	.003	−0.38	.184	−0.44	.207	−0.34	.451
Fat mass	−0.37	.075	0.01	.961	−0.39	.272	0.84	.017
Lean mass	0.68	<.001	0.73	.004	0.16	.659	0.93	.002
Skeletal muscle function
Muscle strength	0.53	.007	0.60	.030	0.21	.584	0.83	.020
Total muscle CSA	0.40	.100	—	—	0.22	.629	—	—

VO_2peak indicates peak oxygen consumption (mL · kg⁻¹ · min⁻¹); CSA, cross-sectional area; KPS, Karnofsky performance status.
a Categorical coding, sex: man=0, woman=1.
b Exercise behavior was defined as the total minutes of exercise/wk.

The univariate predictors of overall QOL and fatigue are shown in Table 5. In patients with HGG, only self-reported exercise behavior was correlated with QOL (r = 0.42, P = .046), whereas sex (men) (r = 0.44, P = .037), LBM (r = −0.41, P = .049), and VO_2peak (r = −0.40, P = .052) were associated with fatigue. In the LGG group, only exercise behavior correlated with QOL (r = 0.68, P = .043), whereas total muscle CSA predicted fatigue (r = −0.74, P = .050).

Table 5. Univariate Predictors of QOL and Fatigue

Variable	High-Grade Patients (n=25)				Low-Grade Patients (n=10)
	QOL		Fatigue		QOL		Fatigue
	r	P	r	P	R	P	r	P
Medical/demographic
Age	−0.09	.680	0.13	.545	−0.18	.642	0.35	.316
Sexa	−0.30	.170	0.44	.037	−0.13	.749	−0.06	.871
KPS	0.08	.726	−0.05	.839	0.64	.045	−0.15	.675
Postsurgery corticosteroid dose	0.07	.759	0.12	.595	0.35	.392	0.15	.697
Exercise behaviorb	0.42	.046	−0.34	.110	0.68	.043	−0.42	.226
Cardiovascular function
VO_2peak	0.30	.175	−0.40	.052	0.40	.289	−0.32	.367
Body composition
Fat percentage	−0.07	.745	0.18	.420	0.25	.512	−0.31	.387
Fat mass	−0.03	.897	0.02	.943	0.34	.375	−0.51	.130
Lean mass	0.24	.267	−0.41	.049	0.28	.461	−0.44	.205
Skeletal muscle function
Muscle strength	0.26	.228	−0.35	.100	−0.04	.980	−0.31	.423
Total muscle CSA	0.18	.565	−0.21	.486	0.60	.204	−0.74	.050

QOL indicates quality of life (Functional Assessment of Cancer Therapy-Brain); KPS, Karnofsky performance status; VO_2peak, peak oxygen consumption (mL · kg⁻¹ · min⁻¹); CSA, cross-sectional area.
a Categorical coding, sex: men = 0, women = 1.
b Exercise behavior was defined as the total minutes of exercise/wk.

DISCUSSION

Primary malignant glioma patients were able to achieve acceptable CPET criteria with a low incidence of complications or exercise-induced abnormalities. This is the first study to investigate the utility of CPET in primary malignant glioma patients, thus, the feasibility and safety of this procedure are not known. Primary glioma patients may represent a population at higher risk of CPET-associated adverse events relative to individuals from the general population. For example, primary gliomas are highly angiogenic, which can lead to increased risk of prothrombotic events31, 32; the addition of extensive cranial surgery and postoperative high-dose steroid therapy may further increase the risk of an event. The present data indicating that CPET is a relatively safe procedure in this setting are, therefore, important. These results are consistent with our recent systematic review indicating that maximal and submaximal exercise testing is a relatively safe procedure in cancer patients, with adverse events being reported in <15% of studies and no reported exercise test-related deaths.12 Clearly, symptom-limited CPETs are likely only appropriate for patients with good PS (ie, KPS ≥70%). The application of CPET, and thus exercise interventions, among malignant glioma patients appears limited to those with better PS and experiencing less therapy (surgery)-related complications. Nevertheless, a CPET or other forms of exercise testing may provide a sensitive and accurate evaluation of functional capacity facilitating individualized therapeutic management.33 Exercise testing recommendations for cancer patients have recently been published.12

A major finding of this study was the significant and marked reduction in VO_2peak in both patient cohorts. Overall, on average, VO_2peak was 13 mL · kg⁻¹ · min⁻¹ or ∼60% below that predicted for age- and sex-matched sedentary comparison data, despite a minimum good KPS eligibility requirement of ≥70%. Relatedly, VO_2peak indexed to LBM as opposed to the traditional index of total body weight may more accurately reflect cardiorespiratory fitness in clinical populations experiencing catabolic disease states and increase the prognostic value of CPET.34-36 By using this approach, mean VO_2peak increased to 19 mL · LBM⁻¹ · min⁻¹, although this value remained ∼38% below that predicted. This VO_2peak is lower than that observed in our prior work among patients with inoperable (advanced) malignancy, patient groups that presented with significant comorbid disease and while undergoing palliative chemoradiation.37, 38 To our knowledge, this is the first study to measure VO_2peak in patients with malignant glioma.

The low VO_2peak may be of clinical importance. VO_2peak is a powerful independent predictor of mortality among noncancer populations with underlying cardiac and pulmonary disease.34, 35 Three studies have reported that subjective functional outcome measures are independent predictors of survival in malignant glioma.39-41 However, these studies assessed functional status using self-assessment questionnaires as opposed to objective, gold-standard physiologic instruments. Relatedly, KPS and other PS scoring systems have been consistently demonstrated to have strong prognostic value in primary malignant glioma.42 The subjectivity of PS scoring systems limits the reliability and validity of these instruments. Relatedly, body weight status, as assessed by the most widely accepted measure—body mass index—was relatively normal; however, percentage body fat (ie, 11%-22% for men; 21%-35% for females) and FM (ie, 13 kg for men; 19 kg for women) were abnormal relative to those considered ideal for age and sex norms. Measures of body composition also are powerful predictors of mortality,5, 15 although the prognostic value of VO_2peak and associated measures of functional status (eg, body composition and skeletal muscle function) in malignant glioma remains to be determined.

The causes (mechanisms) of low VO_2peak in malignant glioma are not known. VO_2peak reflects the integrative capacity of the cardiopulmonary system to deliver adequate oxygen for adenosine triphosphate resynthesis. The presence of malignancy together with comorbid disease and the use of aggressive cancer therapy can simultaneously impact 1 or more components of this system, leading to exercise intolerance.43 However, the mechanisms of the markedly reduced VO_2peak in malignant glioma are less apparent, because patients in this study had unremarkable medical histories and were not receiving any cytotoxic therapy. Nevertheless, several other mechanistic explanations are plausible. First and foremost, patients performed the CPET, on average, 10 days after craniotomy and were likely still in acute surgical recovery. Second, patients were likely deconditioned from a reduction in physical activity from the point of diagnosis to the CPET (an average of 28 days). Indeed, only 1 (3%) patient met the national criteria for regular physical activity postdiagnosis, compared with 40% before diagnosis (data not presented). Deconditioning can have a dramatic adverse effect on cardiopulmonary function.44 Third, the use of high-dose postsurgical corticosteroids may also adversely affect the components that determine VO_2peak and muscle CSA. Intriguingly, postoperative steroid dose was positively associated with these outcomes (among HGG patients only), indicating that steroids improve exercise and functional performance. The reasons for this finding are not clear, although acute steroid administration may attenuate surgery-induced systemic inflammation (inflammation may contribute to exercise intolerance45) and/or attenuate cerebral edema-induced toxicities/symptoms, leading to improved exercise tolerance. Further investigation of this interesting finding as well as the impact of acute versus chronic use of corticosteroids on physiologic parameters appears warranted.

A final and important potential mechanism is an abnormal neurohormonal response to exercise because of disease burden and surgical excision of normal brain tissue. The exercise response is governed by the interplay between central command and afferent information from the exercising muscles.46 The size, location, and infiltration of a malignant brain tumor may impair the autonomic nervous system response, causing dysregulated peripheral sympathetic activation which, in turn, leads to decreased skeletal muscle blood flow and early acidosis. Overall, given the potential clinical significance of poor exercise tolerance in this population, carefully designed studies that identify and unravel the mechanisms of action offer an exciting area of future research.

A final important finding was the association between functional outcomes and patient-reported outcomes. Similar to prior investigations, we found that self-reported exercise behavior was positively correlated with overall QOL,47 although we found no significant correlations for any other clinical, demographic, or physiological variable. However, VO_2peak and LBM (muscle strength approached significance) were inversely associated with fatigue. Fatigue is consistently reported as the primary toxicity in malignant glioma,43 and although the mechanisms remain elusive, our results indicate that impairments in O₂ delivery to and O₂ utilization by the skeletal muscle may play a major role. Our findings further suggest that pharmacologic or nonpharmacologic interventions demonstrated to augment VO_2peak and LBM may improve fatigue in malignant glioma.

This study does have limitations. The most important limitation is patient selection bias because of the relatively low eligibility rate, the transparent purpose of the investigation, and the exclusion of patients with poor KPS (<70%). As such, patients with better KPS, those with less advanced disease, and those experiencing less treatment-related complications were probably more likely to participate in this study. Two other obvious limitations are the relatively small sample size and the cross-sectional study design. To adequately investigative the impact of functional assessments in primary malignant glioma, large prospective studies are required.

In summary, an individualized CPET appears to be a safe and feasible assessment tool to quantitatively evaluate physical functioning in select patients with clinically stable, newly diagnosed and untreated, postsurgical primary malignant glioma. Moreover, malignant glioma patients have markedly reduced exercise tolerance, isokinetic strength, and CSA. These quantitative assessments may complement established markers of outcome in primary glioma and could improve prognostication. Prospective studies are now required to determine whether such abnormalities influence prognosis as well as to test the effect of appropriately selected interventions to prevent and/or mitigate dysfunction.

CONFLICT OF INTEREST DISCLOSURES

Supported from National Institutes of Health Grant CA-126432 (to L. W. Jones)

REFERENCES

1 Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987–996.
10.1056/NEJMoa043330
CASPubMedWeb of Science®Google Scholar
2 Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol. 2006; 24: 1305–1309.
10.1200/JCO.2005.04.6086
PubMedWeb of Science®Google Scholar
3 Jones LW, Haykowsky M, Pituskin EN, et al. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor–positive operable breast cancer. Oncologist. 2007; 12: 1156–1164.
10.1634/theoncologist.12-10-1156
PubMedWeb of Science®Google Scholar
4 Jones LW, Haykowsky M, Peddle CJ, et al. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1026–1031.
10.1158/1055-9965.EPI-06-0870
CASPubMedWeb of Science®Google Scholar
5 Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9: 629–635.
10.1016/S1470-2045(08)70153-0
PubMedWeb of Science®Google Scholar
6 Demark-Wahnefried W, Peterson BL, Winer EP, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001; 19: 2381–2389.
10.1200/JCO.2001.19.9.2381
CASPubMedWeb of Science®Google Scholar
7 Horber FF, Scheidegger JR, Grunig BE, Frey FJ. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab. 1985; 61: 83–88.
10.1210/jcem-61-1-83
CASPubMedWeb of Science®Google Scholar
8 Horber FF, Scheidegger JR, Grunig BE, Frey FJ. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest. 1985; 15: 302–307.
10.1111/j.1365-2362.1985.tb00276.x
CASPubMedWeb of Science®Google Scholar
9 Horber FF, Hoopeler H, Scheidegger JR, Grunig BE, Howald H, Frey FJ. Impact of physical training on the ultrastructure of midthigh muscle in normal subjects and in patients treated with glucocorticoids. J Clin Invest. 1987; 79: 1181–1190.
10.1172/JCI112935
CASPubMedWeb of Science®Google Scholar
10 Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. The Lancet Oncol. 2009; 10: 598–605.
10.1016/S1470-2045(09)70031-2
PubMedWeb of Science®Google Scholar
11 Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol. 2008; 9: 1–22.
10.1007/s11864-008-0052-6
PubMedWeb of Science®Google Scholar
12 Jones LW, Eves ND, Haykowsky M, Joy AA, Douglas PS. Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol. 2008; 9: 757–765.
10.1016/S1470-2045(08)70195-5
PubMedWeb of Science®Google Scholar
13 Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997; 30: 1758–1764.
10.1016/S0735-1097(97)00381-1
CASPubMedWeb of Science®Google Scholar
14 Mettauer B, Zoll J, Sanchez H, et al. Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active control subjects. J Am Coll Cardiol. 2001; 38: 947–954.
10.1016/S0735-1097(01)01460-7
CASPubMedWeb of Science®Google Scholar
15 Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997; 349: 1050–1053.
10.1016/S0140-6736(96)07015-8
CASPubMedWeb of Science®Google Scholar
16 ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003; 167: 211–277.
10.1164/rccm.167.2.211
CASPubMedWeb of Science®Google Scholar
17 Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14: 377–381.
10.1249/00005768-198205000-00012
CASPubMedWeb of Science®Google Scholar
18 Jones NL, Summers E, Killian KJ. Influence of age and stature on exercise capacity during incremental cycle ergometry in men and women. Am Rev Respir Dis. 1989; 140: 1373–1380.
10.1164/ajrccm/140.5.1373
CASPubMedWeb of Science®Google Scholar
19 Fitzgerald MD, Tanaka H, Tran ZV, Seals DR. Age-related declines in maximal aerobic capacity in regularly exercising vs. sedentary women: a meta-analysis. J Appl Physiol. 1997; 83: 160–165.
10.1152/jappl.1997.83.1.160
CASPubMedWeb of Science®Google Scholar
20 Wilson TM, Tanaka H. Meta-analysis of the age-associated decline in maximal aerobic capacity in men: relation to training status. Am J Physiol Heart Circ Physiol. 2000; 278: H829–H834.
10.1152/ajpheart.2000.278.3.H829
CASPubMedWeb of Science®Google Scholar
21 Minotti JR, Pillay P, Oka R, Wells L, Christoph I, Massie BM. Skeletal muscle size: relationship to muscle function in heart failure. J Appl Physiol. 1993; 75: 373–381.
10.1152/jappl.1993.75.1.373
CASPubMedWeb of Science®Google Scholar
22 Wijndaele K, Duvigneaud N, Matton L, et al. Muscular strength, aerobic fitness, and metabolic syndrome risk in Flemish adults. Med Sci Sports Exerc. 2007; 39: 233–240.
10.1249/01.mss.0000247003.32589.a6
PubMedWeb of Science®Google Scholar
23 Muller MJ, Illner K, Bosy-Westphal A, Brinkmann G, Heller M. Regional lean body mass and resting energy expenditure in non-obese adults. Eur J Nutr. 2001; 40: 93–97.
10.1007/s003940170008
CASPubMedWeb of Science®Google Scholar
24 Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008; 149: 601–611.
10.7326/0003-4819-149-9-200811040-00003
PubMedWeb of Science®Google Scholar
25 Collins MA, Millard-Stafford ML, Sparling PB, et al. Evaluation of the BOD POD for assessing body fat in collegiate football players. Med Sci Sports Exerc. 1999; 31: 1350–1356.
10.1097/00005768-199909000-00019
CASPubMedWeb of Science®Google Scholar
26 Fields DA, Hunter GR. Monitoring body fat in the elderly: application of air-displacement plethysmography. Curr Opin Clin Nutr Metab Care. 2004; 7: 11–14.
10.1097/00075197-200401000-00003
PubMedWeb of Science®Google Scholar
27 Fields DA, Higgins PB, Radley D. Air-displacement plethysmography: here to stay. Curr Opin Clin Nutr Metab Care. 2005; 8: 624–629.
10.1097/01.mco.0000171127.44525.07
PubMedWeb of Science®Google Scholar
28 Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995; 75: 1151–1161.
10.1002/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-Q
CASPubMedWeb of Science®Google Scholar
29 Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997; 13: 63–74.
10.1016/S0885-3924(96)00274-6
CASPubMedWeb of Science®Google Scholar
30 Godin G, Jobin J, Bouillon J. Assessment of leisure time exercise behavior by self-report: a concurrent validity study. Can J Public Health. 1986; 77: 359–362.
CASPubMedWeb of Science®Google Scholar
31 Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008; 8: 541–553.
10.1517/14712598.8.4.541
CASPubMedWeb of Science®Google Scholar
32 Lebelt A, Dzieciol J, Guzinska-Ustymowicz K, Lemancewicz D, Zimnoch L, Czykier E. Angiogenesis in gliomas. Folia Histochem Cytobiol. 2008; 46: 69–72.
10.2478/v10042-008-0009-4
PubMedWeb of Science®Google Scholar
33 Jones LW, Cohen RR, Mabe SK, et al. Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol. 2009; 94: 79–85.
10.1007/s11060-009-9803-x
PubMedWeb of Science®Google Scholar
34 Cicoira M, Davos CH, Francis DP, et al. Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue. J Card Fail. 2004; 10: 421–426.
10.1016/j.cardfail.2003.12.009
PubMedWeb of Science®Google Scholar
35 Osman AF, Mehra MR, Lavie CJ, Nunez E, Milani RV. The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. J Am Coll Cardiol. 2000; 36: 2126–2131.
10.1016/S0735-1097(00)00985-2
CASPubMedWeb of Science®Google Scholar
36 Wensel R, Anker SD. Lean tissue adjusted peak oxygen consumption in congestive heart failure. J Am Coll Cardiol. 2001; 38: 287–289.
10.1016/S0735-1097(01)01359-6
CASPubMedWeb of Science®Google Scholar
37 Courneya KS, Jones LW, Peddle CJ, et al. Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial. Oncologist. 2008; 13: 1012–1020.
10.1634/theoncologist.2008-0017
CASPubMedWeb of Science®Google Scholar
38 Jones LW, Eves ND, Mackey JR, et al. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer. 2007; 55: 225–232.
10.1016/j.lungcan.2006.10.006
PubMedWeb of Science®Google Scholar
39 McCarter H, Furlong W, Whitton AC, et al. Health status measurements at diagnosis as predictors of survival among adults with brain tumors. J Clin Oncol. 2006; 24: 3636–3643.
10.1200/JCO.2006.06.0137
PubMedWeb of Science®Google Scholar
40 Tang V, Rathbone M, Park Dorsay J, Jiang S, Harvey D. Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival. J Neurol. 2008; 255: 820–827.
10.1007/s00415-008-0695-z
CASPubMedWeb of Science®Google Scholar
41 Brazil L, Thomas R, Laing R, et al. Verbally administered Barthel Index as functional assessment in brain tumour patients. J Neurooncol. 1997; 34: 187–192.
10.1023/A:1005710729748
CASPubMedWeb of Science®Google Scholar
42 Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3. Lancet Oncol. 2008; 9: 29–38.
10.1016/S1470-2045(07)70384-4
PubMedWeb of Science®Google Scholar
43 Liu R, Page M, Solheim K, Fox S, Chang SM. Quality of life in adults with brian tumors: current knowledge and future directions. Neuro Oncology, 2009; 11: 330-339.
10.1215/15228517-2008-093
PubMedWeb of Science®Google Scholar
44 Saltin B, Blomqvist G, Mitchell JH, Johnson RL Jr, Wildenthal K, Chapman CB. Response to exercise after bed rest and after training. Circulation. 1968; 38( 5 suppl): VII1–VII78.
CASPubMedWeb of Science®Google Scholar
45 Wagner PD. Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy? Respirology. 2006; 11: 681–686.
10.1111/j.1440-1843.2006.00939.x
PubMedWeb of Science®Google Scholar
46 Schunemann M, Anker SD, Rauchhaus M. Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards onco-cardiology. Nat Clin Pract Oncol. 2008; 5: 632–633.
10.1038/ncponc1226
PubMedWeb of Science®Google Scholar
47 Jones LW, Demark-Wahnefried W. Diet, exercise, and complementary therapies after primary treatment for cancer. Lancet Oncol. 2006; 7: 1017–1026.
10.1016/S1470-2045(06)70976-7
PubMedWeb of Science®Google Scholar

Citing Literature

Volume116, Issue3

1 February 2010

Pages 695-704

Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma

Abstract

BACKGROUND: